Annual theme 2025: vaccine-preventable diseases in humans — today's challenges and tomorrow's opportunities Submit your articles nowThree open-access e-learning resources for peer review to evaluate studies' aims, completeness and diversity. Enrol here
Eurosurveillance
Since 1995, Eurosurveillance has provided the European public health community with an open-access platform to exchange relevant findings on communicable disease surveillance, prevention and control. A weekly, electronic, peer-reviewed publication, Eurosurveillance aims to provide timely facts and guidance for public health professionals and decision-makers in the field of infectious disease to facilitate the implementation of effective prevention and control measures. Impact factor: 9.9. More...
Latest Issue: Volume 30, Issue 6, 13 February 2025 Latest Issue RSS feed
- Rapid communication
-
-
-
Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season
Using real-life data from Spain between October 2023 and March 2024, the number needed to immunise (NNI) with nirsevimab and the cost to prevent one RSV hospitalisation were estimated at 90 infants (95% CI: 77–108) and 19,700 EUR for catch-up immunisation, and 41 infants (95% CI: 35–50) and 9,000 EUR for at-birth immunisation. By month of birth, NNI and cost were lowest in infants born shortly before the RSV epidemic peak, with impact decreasing gradually for earlier or later births.
-
-
-
Immediate public health surveillance response to cyclone Chido, Mayotte, 14 December 2024
On 14 December 2024, Cyclone Chido caused extensive damage to infrastructures in Mayotte, including water, electricity and communication networks. Health surveillance systems were no longer functional. Santé publique France provided health risk analyses to support local control measures. Malnutrition and dehydration, follow-up care, pregnancy and post-partum complications, mental health, gastrointestinal diseases, bacterial wound superinfections and bronchiolitis were the main risk identified. The preliminary ad hoc surveillance systems confirmed our analyses. We also present lessons learnt 1 month after the event.
-
-
-
Detections of rare enterovirus C105 linked to an emerging novel clade, Spain, 2019 to 2024
Enterovirus (EV)-C105 is a rare genotype not previously detected in Spain. Between 2019 and 2024, we detected EV-C105 in respiratory samples of five patients, through routine EV surveillance. Three cases had respiratory illness and two were hospitalised for neurological illness. Four of the five sequenced strains belonged to an emerging clade (C1), defined by four novel nonsynonymous mutations in key antigenic epitopes. We recommend reinforced clinical awareness and EV genomic surveillance, including respiratory samples, even when symptoms are neurological.
-
- Top
-
- Research
-
-
-
Molecular screening to track ceftriaxone-resistant FC428-like Neisseria gonorrhoeae strains’ dissemination in four provinces of China, 2019 to 2021
Leshan Xiu , Liqin Wang , Yamei Li , Lihua Hu , Jia Huang , Gang Yong , Youwei Wang , Wenling Cao , Yang Yang , Weiming Gu and Junping PengBackgroundThe global dissemination of ceftriaxone-resistant Neisseria gonorrhoeae FC428-like strains poses a public health concern. To assess and follow their spread, establishing effective antimicrobial resistance (AMR) surveillance systems is essential.
AimThis study aimed to track ceftriaxone-resistant FC428-like strains in parts of China, using a molecular screening tool.
MethodsSamples were collected from Sichuan, Zhejiang, Shanghai, and Guangdong provinces between 2019 and 2021. We employed a rapid molecular tool − the high-resolution melting analysis-based FC428 (HRM-FC428) assay, to screen for FC428-like strains. All FC428-like strains detected were further characterised by genotyping and PCR-sequencing.
ResultsOf 1,042 tested samples, 44 harboured the penA-60.001 allele linked to ceftriaxone resistance, revealing a 4.2% prevalence of FC428-like strains. The HRM-FC428 assay additionally uncovered six strains with mosaic penA-195.001 or penA-232.001 alleles, both bearing the A311V mutation, a ceftriaxone resistance marker. During the study, the prevalence of FC428-like strains among overall samples appeared to increase, with rates of 2.8% (11/395) in 2019, 4.2% (16/378) in 2020, and 6.3% (17/269) in 2021. Some strains’ sequence types (ST)s were identified across provinces (e.g. ST1903, ST1600) and most strains (24/44) were ST1903, an ST also reported in other regions/countries, suggesting local evolution and global transmission.
ConclusionOur work underscores the value of culture-independent antimicrobial resistance monitoring and validates the use of molecular diagnostic tools, like the HRM-FC428 assay for this purpose. This study offers insights into the complex landscape of ceftriaxone-resistant N. gonorrhoeae, emphasising the importance of continued surveillance and global collaboration to mitigate this growing public health threat.
-
-
-
Inferring transmission risk of respiratory viral infection from the viral load kinetics of SARS-CoV-2, England, 2020 to 2021 and influenza A virus, Hong Kong, 2008 to 2012
Jakob Jonnerby , Joe Fenn , Seran Hakki , Jie Zhou , Kieran J Madon , Aleksandra Koycheva , Sean Nevin , Rhia Kundu , Michael A Crone , Timesh D Pillay , Shazaad Ahmad , Nieves Derqui , Emily Conibear , Robert Varro , Constanta Luca , Paul S Freemont , Graham P Taylor , Maria Zambon , Wendy S Barclay , Jake Dunning , Neil M Ferguson , Benjamin J Cowling , Ajit Lalvani and on behalf of the ATACCC Study InvestigatorsBackgroundInfectiousness of respiratory viral infections is quantified as plaque forming units (PFU), requiring resource-intensive viral culture that is not routinely performed. We hypothesised that RNA viral load (VL) decline time (e-folding time) in people might serve as an alternative marker of infectiousness.
AimThis study’s objective was to evaluate the association of RNA VL decline time with RNA and PFU VL area under the curve (AUC) and transmission risk for SARS-CoV-2 and influenza A virus.
MethodsIn SARS-CoV-2 and influenza A virus community cohorts, viral RNA was quantified by reverse transcription quantitative PCR in serial upper respiratory tract (URT)-samples collected within households after an initial household-member tested positive for one virus. We evaluated correlations between RNA VL decline time and RNA and PFU-VL AUC. Associations between VL decline time and transmission risk in index-contact pairs were assessed.
ResultsIn SARS-CoV-2 cases, we observed positive correlations between RNA VL decline time and RNA and PFU VL AUC with posterior probabilities 1 and 0.96 respectively. In influenza A cases a positive correlation between RNA VL decline time and RNA VL AUC was observed, with posterior probability of 0.87. Index case VL decline times one standard deviation above the cohort-mean showed a relative increase in secondary attack rates of 39% (95% credible interval (CrI): −6.9 to 95%) for SARS-CoV-2 and 25% (95% CrI: −11 to 71%) for influenza A virus.
ConclusionWe identify VL decline time as a potential marker of infectiousness and transmission risk for SARS-CoV-2 and influenza A virus. Early ascertainment of VL kinetics as part of surveillance of new viruses or variants could inform public health decision making.
-
-
Recent articles
-
-
A national outbreak of Serratia marcescens complex: investigation reveals genomic population structure but no source, Norway, June 2021 to February 2023
Arne Michael Taxt , Vegard Eldholm , Nicola Isabelle Kols , Maria Schei Haugan , Niclas Raffelsberger , Anne Mette Asfeldt , André Ingebretsen , Anita Blomfeldt , Kristin Stenhaug Kilhus , Paul Christoffer Lindemann , Horst Bentele , Jeanette Stålcrantz , Liz Ertzeid Ødeskaug , Thale Cathrine Berg and The Norwegian Serratia study group
-
-
-
Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case–control study, Spain, 2023/24 season
Olivier Núñez , Carmen Olmedo , David Moreno-Perez , Nicola Lorusso , Sergio Fernández Martínez , Pedro Eliseo Pastor Villalba , Ángeles Gutierrez , Marcos Alonso Garcia , Pello Latasa , Rosa Sancho , Jacobo Mendioroz , Montserrat Martinez-Marcos , Enriqueta Muñoz Platón , María Victoria García Rivera , Olaia Pérez-Martinez , Rosa Álvarez-Gil , Eva Rivas Wagner , Nieves López Gonzalez-Coviella , Matilde Zornoza , M Isabel Barranco , M del Carmen Pacheco , Virginia Álvarez Río , Miguel Fiol Jaume , Roxana Morey Arance , Begoña Adiego Sancho , Manuel Mendez Diaz , Noa Batalla , Cristina Andreu , Jesús Castilla , Manuel García Cenoz , Ana Fernández Ibáñez , Marta Huerta Huerta , Ana Carmen Ibáñez Pérez , Belén Berradre Sáenz , Joaquín Lamas , Luisa Hermoso , Susana Casado Cobo , Manuel Galán Cuesta , Sara Montenegro , María Domínguez , Inmaculada Jarrín , Aurora Limia , Roberto Pastor-Barriuso , Susana Monge and the Nirsevimab Effectiveness Study Collaborators
-
-
-
Tick-borne encephalitis: from tick surveillance to the first confirmed human cases, the United Kingdom, 2015 to 2023
Helen Callaby , Kate R Beard , Dominic Wakerley , Mary Alexandra Lake , Jane Osborne , Kevin Brown , Nadina Wand , Jenny Warner , Maya Holding , Nicholas WS Davies , Malcolm Proudfoot , Amanda Semper , Tim Brooks , Christina Petridou , Catherine F Houlihan , Tommy Rampling , Clare E Warrell , N Claire Gordon and the TBE working group
-
-
-
One health investigation following a cluster of Crimean–Congo haemorrhagic fever, North Macedonia, July to November 2023
Dejan Jakimovski , Pavle Banović , Katerina Spasovska , Goran Rangelov , Marija Cvetanovska , Fadil Cana , Verica Simin , Ivana Bogdan , Dragana Mijatović , Aleksandar Cvetkovikj , Igor Djadjovski , Iva Christova , Eleftherios Meletis , Polychronis Kostoulas , Brigitta Zana , Zsófia Lanszki , Tamás Görföl , Zsófia Tauber and Gabor Kemenesi
-
-